Tags

Type your tag names separated by a space and hit enter

Incidence and risk of treatment for benign prostatic hyperplasia in Japanese men: a 15-year longitudinal community-based study.
Int J Urol 2013; 20(1):100-6IJ

Abstract

OBJECTIVES

To determine the incidence of and the risk factors for treatment in Japanese men with benign prostatic hyperplasia/lower urinary tract symptoms enrolled into a longitudinal community-based study.

METHODS

A total of 267 of 319 men aged 40-79 years were eligible for this study, with nearly 15 years of follow up. Their medical records were checked to look for any medical treatment for benign prostatic hyperplasia/lower urinary tract symptoms. The risk of treatment for benign prostatic hyperplasia/lower urinary tract symptoms was determined by calculating the hazard ratio using the Cox proportional hazards model. Five baseline parameters were considered: the International Prostate Symptom Score, the peak urinary flow rate, the prostate volume, the serum prostate-specific antigen and the internal prostatic architecture on transrectal ultrasonography.

RESULTS

Data were successfully collected for 171 men (64%; 121 survivors and 50 deceased). During approximately 1900 person-years of follow up, the overall incidence of treatment for benign prostatic hyperplasia/lower urinary tract symptoms was 15.4/1000 person-years. All five parameters were statistically significant predictors of future treatment for benign prostatic hyperplasia/lower urinary tract symptoms: International Prostate Symptom Score greater than 7 (hazard ratio 6.2, P < 0.001), prostate volume greater than 30 mL (hazard ratio 4.3, P = 0.002), peak urinary flow rate less than 12 mL/s (hazard ratio 4.4, P < 0.001), prostate-specific antigen greater than 1.4 ng/mL (hazard ratio 4.0, P < 0.001) and internal prostatic architecture group 3 (hazard ratio 3.2, P = 0.002).

CONCLUSIONS

Severity of lower urinary tract symptoms, decreased peak urinary flow rate, enlarged prostate volume, high prostate-specific antigen value and internal prostatic architecture at baseline are independent risk factors for treatment in Japanese men presenting with benign prostatic hyperplasia/lower urinary tract symptoms.

Authors+Show Affiliations

Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, Japan.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23106204

Citation

Fukuta, Fumimasa, et al. "Incidence and Risk of Treatment for Benign Prostatic Hyperplasia in Japanese Men: a 15-year Longitudinal Community-based Study." International Journal of Urology : Official Journal of the Japanese Urological Association, vol. 20, no. 1, 2013, pp. 100-6.
Fukuta F, Masumori N, Mori M, et al. Incidence and risk of treatment for benign prostatic hyperplasia in Japanese men: a 15-year longitudinal community-based study. Int J Urol. 2013;20(1):100-6.
Fukuta, F., Masumori, N., Mori, M., & Tsukamoto, T. (2013). Incidence and risk of treatment for benign prostatic hyperplasia in Japanese men: a 15-year longitudinal community-based study. International Journal of Urology : Official Journal of the Japanese Urological Association, 20(1), pp. 100-6. doi:10.1111/j.1442-2042.2012.03215.x.
Fukuta F, et al. Incidence and Risk of Treatment for Benign Prostatic Hyperplasia in Japanese Men: a 15-year Longitudinal Community-based Study. Int J Urol. 2013;20(1):100-6. PubMed PMID: 23106204.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Incidence and risk of treatment for benign prostatic hyperplasia in Japanese men: a 15-year longitudinal community-based study. AU - Fukuta,Fumimasa, AU - Masumori,Naoya, AU - Mori,Mitsuru, AU - Tsukamoto,Taiji, Y1 - 2012/10/29/ PY - 2012/07/26/received PY - 2012/09/27/accepted PY - 2012/10/31/entrez PY - 2012/10/31/pubmed PY - 2013/7/3/medline SP - 100 EP - 6 JF - International journal of urology : official journal of the Japanese Urological Association JO - Int. J. Urol. VL - 20 IS - 1 N2 - OBJECTIVES: To determine the incidence of and the risk factors for treatment in Japanese men with benign prostatic hyperplasia/lower urinary tract symptoms enrolled into a longitudinal community-based study. METHODS: A total of 267 of 319 men aged 40-79 years were eligible for this study, with nearly 15 years of follow up. Their medical records were checked to look for any medical treatment for benign prostatic hyperplasia/lower urinary tract symptoms. The risk of treatment for benign prostatic hyperplasia/lower urinary tract symptoms was determined by calculating the hazard ratio using the Cox proportional hazards model. Five baseline parameters were considered: the International Prostate Symptom Score, the peak urinary flow rate, the prostate volume, the serum prostate-specific antigen and the internal prostatic architecture on transrectal ultrasonography. RESULTS: Data were successfully collected for 171 men (64%; 121 survivors and 50 deceased). During approximately 1900 person-years of follow up, the overall incidence of treatment for benign prostatic hyperplasia/lower urinary tract symptoms was 15.4/1000 person-years. All five parameters were statistically significant predictors of future treatment for benign prostatic hyperplasia/lower urinary tract symptoms: International Prostate Symptom Score greater than 7 (hazard ratio 6.2, P < 0.001), prostate volume greater than 30 mL (hazard ratio 4.3, P = 0.002), peak urinary flow rate less than 12 mL/s (hazard ratio 4.4, P < 0.001), prostate-specific antigen greater than 1.4 ng/mL (hazard ratio 4.0, P < 0.001) and internal prostatic architecture group 3 (hazard ratio 3.2, P = 0.002). CONCLUSIONS: Severity of lower urinary tract symptoms, decreased peak urinary flow rate, enlarged prostate volume, high prostate-specific antigen value and internal prostatic architecture at baseline are independent risk factors for treatment in Japanese men presenting with benign prostatic hyperplasia/lower urinary tract symptoms. SN - 1442-2042 UR - https://www.unboundmedicine.com/medline/citation/23106204/Incidence_and_risk_of_treatment_for_benign_prostatic_hyperplasia_in_Japanese_men:_a_15_year_longitudinal_community_based_study_ L2 - https://doi.org/10.1111/j.1442-2042.2012.03215.x DB - PRIME DP - Unbound Medicine ER -